Assi

gnment

On

Theper
for
manceoft
he

Squar
ePhar
maceut
ical
sLt
d.

Pr
epar
edby
Team OfTomor
row

Name I
D I
ntake Sect
ion Mar
k

Md.Abul
Hossen 21223101074 58 02

Ani
kaAkt
erTonni 21223101089 58 02

TamannaJaman 21223101080 58 02

Ni
j
hum Akt
erBar
sha 21223101060 58 02

Md.Li
mon 21223101061 58 02

Submi
tt
edt
o

Suni
taNasr
in
Assi
stantpr
ofessorofmanagement(
BUBT)

1
Dat
eofsubmi
ssi
on:
08/
11/
2022

Let
terOfTr
ansmi
tt
al

Suni
taNasr
in

Assi
stantpr
ofessor

Depar
tmentofmanagement

Bangl
adeshUni
ver
sit
yOfBusi
nessAndTechnol
ogy

Sub:
Submi
ssi
onofi
nter
nshi
prepor
t

Madam,

Iam herebysubmit
ti
ngmyi nter
nshiprepor
t,whi
chisapartoftheBBApr ogr
am
cur
ri
culum.Itisgr
eatachiev
ementt oworkunderyouract
ivesuper
visi
on.Thisr
epor
tis
on recruit
mentandselecti
onperformanceofSquarePharmaceut
ical
sLt d.

Itr
iedmylevel
besttocompl etet
hisrepor
tproper
lyandtoproduceameaningf
ulr
epor
t
wit
hinall
theconstr
aint
s.Iconcentr
atedonareasthatIbel
iev
edwouldbethemost
rel
evantt
omaket hereportcoher
entaswellaspracti
calaspossi
ble.

Ishal
lbehighl
yobli
gedifyouar
ekind,
enoughtor
eceiv
et hi
srepor
tandprov
ideyour
v
aluabl
ejudgment
.Iwoul dbegladt
ofurni
shyouwit
hanyclari
fi
cat
ion,
ifr
equir
ed.I
t
heref
oresubmiti
t,hopi
ngthaty
ouwouldexcuset
hemi norf
laws.

Si
ncer
elyYour
s

Md.Abul
Hossen

I
D:21223101074

2
 Acknowl
edgement
Fir
stofall
Iwoul
dl i
ketoexpr
essoursat
isf
acti
ontotheal
might
yAl
l
ahf
or
render
ingusabi
l
ityandknowledget
oprepar
ethisassi
gnment
.

Iwouldl i
ketoofferourear
nestthanksandgr
ati
tudet
oourr
espect
abl
e
teacherSunitaNasri
ndepartmentofmanagementwhohasbeenour
i
nstructorforthi
swor k.

Ifi
rmlybel
ievethattheworkont hi
sstudyhelpmetobetterunder
standand
i
ncreaseknowledgeonov erall
aspectoftheperf
ormanceoftheSquare
Pharmaceuti
calsLtd.Hopefull
yall
ofthisaboveworkwhichisdone
thr
oughthisassignmentwil
l behelpf
ulforourf
utur
ecareer.

3
 Execut
ivesummar
y
SquarePhar maceutical
sLt d.Companyr epor tprovi
desacompl et
e
overv
iewoft hecompany ’
saf f
airs.Al
lavailabledataispresentedina
compr ehensi
v eandeasil
yaccessedf or
mat .Thereportcontainst
he
company ’sprofi
leandinformationaboutt hecompany ’
sv i
sion,missi
on
pri
ncipalacti
viti
es,signi
ficance, obj
ect
ives, l
ocati
onsandor gani
zati
on
str
ucture.

Ther eportalsoincludesf i
nancial
infor
mation,
SWOTanal ysi
s,l
atest
developmentofanal ysis,opt
ions,soci
alr
esponsibi
li
ti
es,productscheme
andcur rentachievement .TheSWOTanal y
sisprovi
desinformati
onabout
thecompany ’sstr
engt hs,weakness,opport
uni
ties,
andpossi bl
ethreat
s
againstit.

Thisreportprovi
desrel
evantnews,ananal
ysi
sofR&Dact ivi
ty,
dist
ri
but
ion
channelandst ockpr
icemov ement
s.Thereportal
soenablesdir
ect
compar i
sontobemadebet weenSquarePharmaceut
ical
sLtd..andit
s
compet i
tors.

4
 Tabl
eofcont
ent
s
i
. Let
teroft
ransmi
tt
al…………………………………………………….
.02

i
i
. Acknowl
edgement
……………………………………………………….
.03

i
i
i. Execut
ivesummar
y………………………………………………………04

Chapt
er-
1

i
v. I
ntr
oduct
ion………………………………………………………………….
07

v
. Si
gni
fi
canceofr
epor
t…………………………………………………….
08

v
i. Obj
ect
ivesofr
epor
t………………………………………………………09

v
ii
. Met
hodol
ogyofdat
acol
l
ect
ion…………………………………….
..
10

A.Pr
imar
ysour
ces……………………………………………………….
10

B.Secondar
ysour
ces………………………………………………….
.10

C.Pr
imar
ydat
a…………………………………………………………….
.11

D.Secondar
ydat
a…………………………………………………………11

E.Sampl
i
ngmet
hod…………………………………………………….
.11

1.Sampl
esi
zeandpopul
ati
on………………………………………11

F.Dat
apr
esent
ati
on…………………………………………………….
12

Vi
i
i Li
mit
ati
onsoft
her
epor
t………………………………………………………12

Chapt
er2

5
 i
. Ov
erv
iew…………………………………………………………………………13

i
i
. Hi
stor
ical
backgr
ound………………………………………………………14

i
i
i. Vi
sion……………………………………………………………………………….
15

i
v. Mi
ssi
on…………………………………………………………………………….
15

v
. Goal
……………………………………………………………………………….
..
15

Chapt
er3

i
. SWOTanal
ysi
sofsquar
ephar
maceut
ical
s……………………………….
..
.16

A.St
rengt
hs…………………………………………………………………17-
18

B.Weakness……………………………………………………………….
.19

C.Oppor
tuni
ti
es………………………………………………………….20

D.Thr
eat
s………………………………………………………………….
..
21

Chapt
er4

i
. Recommendat
ion………………………………………………………………………….
.22

i
i
. Concl
usi
on…………………………………………………………………………………….
.23

i
i
i. Ref
erence………………………………………………………………………………………24

6
 Chapt
er-one

I
ntr
oduct
ion

Squar
ePhar
maceut
ical
sLt
d.I
sthel
argestphar
maceut
ical
companyi
n

7
Bangladeshandithasbeenconti
nuousl
yinthe1stposi
ti
onamongal l
nati
onalandmultinat
ional
companiessi
nce1985.Itwasestabl
ishedi
n
1958,conver
tedintoapubli
cli
mitedcompanyin1991andli
stedwithstock
exchangesin1995.
Inacar eerspanni ngacr ossf ourandhal fdecadesi thaspi oneeredt he
dev elopmentoft helocal businessi nf ieldsasdi v er
seasPhar maceut i
cals,
Toi l
et ri
es,Gar ment s, Text ileinformat iont echnology ,Healthproduct s,
Hospi taletc.Wi thanav erageannual tur noverofov erUS$200mi llionanda
wor kf orceofabout3500t hesquar egr oupi sat rueiconoft heBangl adesh
busi nesssect or.Squar ePhar maceut i
cal sLt disthephar maceut ical sgiant
i
nt hecount ry,isat r
ust ednamei nt hei ndustryofmanuf acturi
ngqual it
y
medi cinesf ormor et hanf ourdecade.Squar eusnowanact ivecor por ate
gianti nt hef i
eldsofbusi nessandi ndust ry.Beximcophar maceut ical s,
Incept aphar maceut ical sar et hedi r
ectcompet it
orofsquar e
phar maceut icalsLtd.Thephar maceut ical sectorisahi gh-technol ogyand
knowl edge-i ntensivei ndust r
y.Thei ndust ryhasat wo-t
ierstructure.The
l
ar gestf i
rmsaccountf ort hemaj orit
yoft heR&Di nvestmenti nthei ndustry
andhol dthemaj ori
tyofpat ent s.Ther ear elargenumberofsmal l
erf ir
ms
produci ngmost lyforl ocal mar kets.Thephar maceuticalindustr
yi sheav ily
regul ated.

Si
gni
fi
canceofr
epor
t

Researchr eportisconsi
deredamaj orcomponentoft her
esearchst udyfor
theresearcht askremainsincompleteti
ll
thereporthasbeenpr esented
and/orwr i
tten.Asamat t
eroffacteventhemostbr il
li
anthypothesis,hi
ghly
well
designedandconduct edresearchstudy,andthemostst r
iking
general
izationsandf i
ndingsareoflit
tl
ev al
ueunlesstheyareeffect
ively
8
communi catedtoot her s.
Thepur poseofr esearchisnotwellservedunless
thefindi
ngsar emadeknownt oot her
s.Researchresult
smust invari
ably
enterthegeneralstoreofknowl edge.Al l
thi
sexplainsthesi
gnif i
canceof
writi
ngresearchrepor t.Therearepeopl ewhodonotconsi derwr it
ingof
reportasanintegralpar tofther esearchprocess.Butthegener alopini
oni
s
i
nf avouroftreat
ingt hepr esentati
onofr esearchresul
tsorthewr iti
ngof
reportaspartandpar celofther esearchproj
ect.

Wr i
ti
ngofreportisthelaststepi naresearchst
udyandr equi
resasetof
skil
lssomewhatdi ff
erentfrom thosecal
ledfori
nr espectoftheearl
ier
stagesofresearch.Thistaskshouldbeaccompl ishedbyt heresear
cher
withut
mostcar e;hemayseekt heassistanceandgui danceofexper
t sf
or
thepurpose.

Obj
ect
iveofr
epor
t
Thepri
meobject
iveoft
herepor
twi
l
lbet
oev
aluat
etheexecut
ive.Someof
thei
mport
antobj
ecti
vesar
e-

i
. Toi
dent
if
ydi
rect
orsandmanagementposi
ti
onhi
erar
chy
.

i
i
. Toi
dent
if
yther
esponsi
bil
i
tyofev
erydepar
tmentoft
hecompany
.
9
i
i
i. Todetermineift
heyaresat
isf
iedwi
tht
hei
rwor
kinr
elat
iont
othe
char
acteri
sti
csofwork.

i
v. Toi
dent
if
yift
heyar
esat
isf
iedwi
tht
hei
rsal
ari
esandbenef
it
swor
k.

v
. Todeter
minet
hel
evelofemploy
eesat
isf
act
ionwi
tht
hei
rwor
kin
rel
ati
ontot
hewor
kingenvi
ronment
.

v
i. Toi
dent
if
yift
heyar
ewi
tht
hei
rwor
kincommuni
cat
ion.

v
ii
. Toident
if
ythel
evel
ofemployeesat
isf
act
ionr
egar
dingt
hepr
omot
ion
andgrowthoft
heorgani
zat
ion.

10
 Met
hodol
ogyofdat
acol
l
ect
ion
Bothpr
imaryandsecondarysourcesofi
nfor
mat
ionhavebeenconsi
dered
asadatacoll
ecti
onprocess.Pr
imarydat
awascoll
ect
edthroughcheckl
ist
andper
sonnelint
erv
iew.

Thesecondar yi
nfor
mationoft
hestudywascollectedfr
om thewebsit
es,
publi
shedlit
erat
ure,r
esear
chpapersandvar
iousr epor
ts(i
nter
naland
exter
nal)ofthesamplefi
rms.Qual
i
tati
vet
echniquewasusedt oanal
yze
thecoll
ecteddata.

Pr
imar
ysour
ces-

Pri
mar ysourcesofi
nfor
mat i
onaret hoset
hatprovi
def i
rst
-hand
accountsoftheevent
s,practi
ces,orcondi
ti
ons.Ingeneral
,theseare
documentsthatwerecreatedbywi t
nessesorfi
rstrecor
dersofthese
eventsatabouttheti
met heyoccurr
ed.Theseinfor
mat i
onare
coll
ectedfr
om

i
. Pr
act
ical
deskwor
k

i
i
. Facet
ofaceconv
ersat
ionwi
tht
heof
fi
cer

i
i
i. Di
rectobser
vat
ions

i
v. Facet
ofaceconv
ersat
ionwi
thcl
i
ent

Secondar
ysour
ces-

Second-handpubl
ishedaccountsarecall
edsecondarysources.They
arecall
edsecondarysourcesbecausetheyarecr
eatedafterpri
mary
sourcesandtheyoftenuseortalkaboutpri
marysources.Secondary
sourcescangiveaddit
ionalopi
nionsonapasteventoronapr imary
source.Secondar
ysour cesoft
enhavemanycopi eswhichwe
coll
ectedfrom

11
 i
. Of
fi
cial
recor
dsofSquar
ePhar
maceut
ical
sLt
d.

i
i
. Relev
antf i
l
est
udyaspr
ovi
dedbyt
heof
fi
cer
s
concerned.

i
i
i. Annual
repor
t

i
v. Wor
kingpaper
s

v
. Of
fi
cef
il
es

v
i. Sel
ect
edbooks

v
ii
. Pr
int
edf
orms

v
ii
i. Publ
i
shed&unpubl
i
sheddocument

i
x. Websi
te

x. Dai
l
ydi
ary

Pr
imar
ydat
a-

Datathathasbeengener atedbytheresearcherhimselforher
sel
f,
surv
ey s,i
ntervi
ews,exper
iments,speci
all
ydesignedfor
understandingandsolvi
ngt her
esearchproblem athand.

Secondar
ydat
a–

Usingexi
sti
ngdat agener
atedbylargegov er
nmentinst
it
uti
ons,
healt
hcar
efacil
it
ies,companiesi
nformation,aspar
toforgani
zat
ional
recor
dkeeping.Thedataisthenextract
edf r
om morevari
eddatafi
les.

Sampl
i
ngmet
hod-

Therear
et woty
pesofpopulati
ons’si
ze,
basedonwhichdi
ffer
ent
sampleswere dr
awn.Formanagementnosamplingi
sneeded,
becausearever
yfewHRper sonnel
.Foremploy
ees,
random sampl
i
ngwas
chosen.

12
Sampl
esi
zeandpopul
ati
on-

Popul
ati
onoft
hisr
esear
char
etwot
ypes:

1)Managementofpharmaceut
ical
companies:I
tincl
udestheviewof
theper
sonnel
whoar einv
olv
edintheperf
ormanceappraisal
and
employeemoti
vat
ioninHRdepartment
.

2)Empl
oyeesofphar
maceut
ical
compani
es:
Thegener
alempl
oyeesof
some

Dif
ferentphar
maceut
ical
companiesi
ncl
udet hosewhohad
undergonesomeperf
ormanceapprai
sal
.Iti
ncludesmai
nlyt
hesal
es
off
icers.

Dat
apr
esent
ati
on–

Wehav epresent
edthedat
athroughpi
echart
,whi
chshowsthe
cor
respondingyear
sandtherequi
redi
nfor
mati
onandalsot
heper
cent
ages.

Repor
tWr
it
ingTechni
que

Asthisreporti
spreparedonthebasi
sofdat acol
l
ect
edfrom t
wosour ces
andnoqual i
tati
vemeasurementisused.I
tisadescr
ipt
iver
eportand
i
ncludesdiff
erentsegmentofHRactivi
ti
es.

Li
mit
ati
onsoft
her
epor
t
Ont
hewayofourst udy,wehavefacedsomeprobl
emst hatt
ermedasthe
l
imi
tat
ionsofthest
udy.Inall
respectf
oll
owi
ngl
imitat
ionandweakness
r
emainwithi
nwhichfai
ledtoescapebyanymeans.Thesearefol
l
ows:

13
i
. Budgetedt
imeli
mit
ati
on:Itwasoneoft
hemai
nconst
rai
ntst
he
hi
nderedtocov
eral
laspectsoft
hest
udy.

i
i
. Confi
denti
ali
tyofdat a:
Becauseofsomedivisionalandconfidenti
al
probl
em,wecoul dnotgetenoughinfor
mat i
on.Ev er
yorganizati
onhas
thei
rownsecrecyt hati
snotreveal
edtoothers.Whilecoll
ectingdata
somecompanyper sonneldi
dnotdiscl
oseenoughi nfor
mat i
onf orthe
sakeofconfi
dentiali
tyoft
heorgani
zati
on.

i
i
i. Datainsuff
ici
ency:Thereisal ackofi nf
ormati
onaboutthedif
ferent
costi
ngmet hodsappliedbydi ffer
entcompaniesandthelevelof
costi
ngappl i
cati
onsaswel l
.Insuff
ici
entbookspubli
shedrel
evantto
thetopicandlackofav ai
labil
ityoffactandfi
gurehasmadeani mpact.
Theseconst r
ainsnarrowedt hescopeofaccur at
eanalysi
s.I
fthese
l
imitat
ionshadnott here;thereportwouldhavebeenmor euseful
att
racti
ve.

Chapter -
two
Over
view
Squar ePhar maceut i
cals(DSE:SQURPHARMA, CSE:SQURPHARMA) ,t
hef l
agshi pcompanyof
Squar eGr oup,isthelargestphar maceuti
calscompanyinBangl adesh.Thecompanywas
establishedi n1958asapar t
ner shipf
irm byLateSamsonH.Chowdhur y.Itwasi ncorpor
atedasa
priv
at elimitedcompanyi n1964.Thecompanywasconv er
tedt opubli
climit
edcompanyi n1991and
gotlistedint hestockexchangesi n1995.Thecompanyi sholdingthehighestposi t
ioninthe
i
ndust rysince1985andi taspirestobecomeahi gh-
perf
ormancegl obalplayer.Thecompany
start
edi tsexpor t
ingbusinessin1987andnowexpor tst
omor et han43count riesaroundthe
globe.1
 I
nfinancialyear2019-20, t
hecompanyexpor tsamount edtoTk165cr ore,an11%i ncr
ease
yearony ear.

14
SquarePharmaceut i
calshasanauthorisedcapi talofTk10, 000mill
ionandpai d-upcapi t
alofTk
8,864.
51mill
ion.Thef aceval
ueofthecompanyshar ei
sTk10each.Gener alpublicholds36.25%of
thetot
alshar
es; sponsors,f
orei
gners,andi nsti
tuti
onshold34. 57%,18.61%, and10. 57%,respecti
vel
y.
Thecompanyempl oys9,500+people.Squar ePhar maceuticalshastwosubsi diarycompani es–
SquarePharmaceut i
calsKenyaEPZLt d.,andSquar eLifesciencesLtd.Corporateheadquar terofthe
companyissituati
oninMohakhal i
Commer cialArea,Dhaka, Bangl
adesh.

Thecompanyf ocusesonthequal
it
yoft heproducedmedi cines.I
thasbeensuccessf uli
n
maintai
ningthequali
tyoftheproduct
shencei thol
dsthetopphar maceutical
sexporter
’spositi
onin
Bangladesh.Thecompanymai ntai
nsateam ofscienti
fi
cphar maceutical
sexper
tswhocont inuously
conductresearch&dev el
opmentworkstoinnovatenewpr oducts,
impr ov
equali
ty,andreducecost
ofproducts.SquarePharmaceuti
cal
scurr
entlyproduces859pr oducts.Amongthem 637ar e
pharmaceutical
s,134areagrovet
,36arepesti
cides,30areherbal,14pell
ets,
and8basi cchemi cal
s.

Hi
stor
ical
Backgr
ound
Square Pharmaceutical
s Ltd.
,i st he l
argestpharmaceuti
cals company of
Bangl
adesh,isar eputednamei nthepharmaceuti
cali
ndustr
yofBangladeshfor
manufactur
ing quali
tymedi ci
nesf ormoret han 
fourdecades.SPLmadei ts
debutinahumbl ewayi n1958f r
om asmal lhouseofthevil
lageAtaikol
anear
Pabna.

The fir
stpropri
etar
ymedici
ne was i
ntr
oduced i
n 1959 underthe name of
Easton’
sSyrup,whenthenumberofworki
ngpeoplewas12,t ur
noverwasTk.
55000/-andoccupiedafl
oorspaceof3000sq.f
t.Mr.SamsonChowdhur y
,the
15
owneroft hetransferr
edt henewlyest abli
shedcompanyt oPabnawher eaf ew
people were accepted as co-workers accumul ate more capitalforsmoot h
operat
ionoft hecompany .Thef i
rstpr ocessedt abl
etwasi nt
roducedin1962
underthegener i
cnameSant oni
n.Int henexty eartheintroduct
ionofPathedine
i
njecti
onacceleratedthegr owthoft hef i
rm withar api
dex pansionofbusiness
tur
nover.I
n1964,t heannualturnoveroft hecompanyr oset oTk.1mi l
l
ionand
theSquarePhar maceutical
swasconv ert
edintoPrivateLimitedCompany.

Thecompanycont i
nued to engageitselfinmanuf act
uri
ng ofbothof fici
al’s
preparati
onandar angeofpr opr
iet
aryi
tems.I nthemeant i
met hecompanyhad
beenont helookoutofanacqui ri
ngknow- how andexperti
sefrom outsidef or
manuf actur
ing and mar ket
ing ofmor e sophisti
cated pr
oductsthrough j oin
ventureandcol laborat
ion.Thecompanyt ooknecessarystepsinadopt i
nga
strat
egicplant oexpandi tsmanuf act
uringfaci
lit
iestoproducewider angeof
essentialit
emswi t
hinthepar ameteroft heWHO ( WorldHealthOrganizati
on)
recommendat ions.

Thisenabledthecompanyt omarketawi der angeofpr oductstofil

lupthegap
createdbyt henew dr ugpol
i
cy,in1982,whent urnov
err eachedt oTk.2240
mill
ionandnumberofpeopl eemployedincreasedt onearly400.In1985Squar e
becomet hemarketleaderi
nphar
maceut i
calssector.Asapi oneer,SPLhasbeen
exporti
ngitsant
ibi
oticsandot
herproductstoUK, Singaporeandot hercount
ries
si
nce1986.I nI987,Squaresetup new f actor
yt o meetexpandi ng market
demand.

Vi
sionandMi
ssi
on
1)Vi
sionSt
atementOfSquar
ePhar
maceut
ical
s:
Wev
iewbusinessasameanstot
hemat er
ialandsocialwel
l
beingof
t
hei
nvest
ors,empl
oyeesandt
hesoci
etyatlarge,
leadi
ngtoaccret
ion

16
 ofweal
tht
hroughfi
nanci
alandmor
algai
nsasapar
toft
hepr
ocess
oft
hehumancivi
li
zati
on.

2)Mi
ssi
onSt
atementofsquar
ephar
maceut
ical
s:
OurMissionistoproduceandprov
idequali
ty&innovati
vehealt
hcare
rel
ieff
orpeople,maint
ainst
ri
ngent
lyethi
calst
andardinbusiness
operat
ionalsoensuri
ngbenefi
ttotheshar
eholder
s,stakehol
dersand
thesociet
yatlar
ge.

Goal
Thegoal
sofSquar
ePhar
maceut
ical
sar
e-

I
. Developar eal
ist
icdepositmobili
zat
ionplan.Str
engthen
operati
onindomest i
ctoincr
easemar ketshareandprofi
tabi
l
ity
tooffermor evaluetothesharehol
dersoffercont
ract-
manuf act
uringfacil
i
ty.

I
I. Manufact
ureandmar
ketti
medemandedandinter
nat
ional
st
andardphar
maceut
ical
indomest
icandexpor
tmarket.

I
II
. Associ
ati
onwit
hgl obal
resear
chbasedpharmaceut
ical
companyformarketi
ngormanufact
uri
ngtheirpr
oducts.

17
 Chapt
er-
Thr
ee
SWOTanal
ysi
sofsquar
ephar
maceut
ical
s
ASWOTanal y
sisidenti
fi
esandassessest hestrengt
hs,weaknesses,
opportunit
iesandt hr
eatsanorganizat
ionfaces.SWOTanal ysi
softheSPL
i
ll
ust r
atestouppermanagementwhatt hecompanyi sexcelli
ngin,what
i
mpr ovement sneedt obemade, wheregrowthispossibleandwhat
preempt i
vemeasur esneedtobet akentoprotectsharehol
derorcompany
value.

18
 St
rengt
hs
Thest rengt hofSquar ePhar maceut icalsLt d.liesi nit
sdi v
er si
fiedproducts
anddosagef orms.SPLhasbeenpr oduci ngsol i
dpr oduct sl i
ket abl
etsand
capsul esandl iqui
dpr oduct sl
ikesy rup, suspensi onandsol ution,aswellas
semi sol i
dpr oductslikecr eam andoi ntment .Itist hepioneercompanyt o
manuf act ureandmar ketnasal sprays,inhal ati
onaer osol sand
supposi toriesinBangl adesh.Col i
coni sitsinject ablepr oduct .Itisa
prepar ationofCef tri
axone, whichi sconsi der edasabr eakt hrough
antibiotici nt hehistoryofmedi ci
ne.Recent lyCol iconispr edictedtobeone
ofitsl eadi ngbr andsi nt ermsofsal esr evenue.Thecompanyhasl otof
diversifiedpr oductslike, Ofkof, Tusca, Neot ec, Seclo,et c.Itsstrengthscan
beanal yzedasunder .

i
. SPLhasskill
edscientist
s/techni
cians/managementpersonnelat
aff
ordabl
ecostleadi
ngt olowcostofi nnovation/
manufact
uri
ng/capexcost s/expendit
uretor uncGMP(cur
rentGood
Manufact
uri
ngPr act
ice)compl i
ancefacili
ti
esandhighquali
ty
documentat
ionandpr ocessunderstanding.

i
i
. SPLhaswel ldev
elopedchemist
ry,R&Dandmanuf act
uri
ng
i
nfrast
ructur
ewithproventr
ackrecor
dinadvancedchemistr
y
capabi
lit
ies,
desi
gnofhi ght
echmanufact
uri
ngf aci
l
iti
esand
regul
atorycompli
ance.

i
i
i. Thehealt
hydomesticmarketwithri
singpercapit
aexpendit
ureis
anot
hersigni
fi
cantst
rengthenabli
ngachievementofeconomiesof
scal
e.SPLalsohasastrongmar ket
ing&distr
ibuti
onnetwork.

i
v. IthasCompanyStr
engt
h&productst
rengt
h,Companyst
rengths
effect
sposi
ti
vel
yonthepr
oduct
,&product
sstrengt
hal
soeffect
s

19
 posi
ti
vel
yont
heCompany
.

v
. Squarehashi
ghlyski
ll
edsal
esf
orces&v
eryef
fi
ci
ent&wi
de
di
stri
buti
onchannel
s.

v
i. Squar
eranked&hel
dtheFir
stposi
ti
oninPharmaceuti
cal
sIndust
ry
si
nce1985,whi
chmeansiti
sinthetopforl
ast28year
s.

v
ii
. Beinginthet
opforthi
slongtimeresul
tedinav er
yposit
ive
i
mpr essi
onforal
lourproduct
sinthemi ndsofthedoct
ors&pat
ient
s
al
ready,i
toccupi
esagoodposi t
ionitt
heirminds.

v
ii
i. Thebuil
tinposit
ivei
mpressi
ononourproductswhichisi
ntheminds
ofthedoctors&pati
ent
shelpsustogetaverygoodresponsef
rom
themarketforanypr
oductweint
roducei
nthemar ket.

i
x. Wecansayv eryconfi
dentl
ythatthenumberofsalesforceofthe
company,
theircapabil
i
ty,
Traini
ng&sell
i
ngskil
lsareinbetter
condi
ti
on&posi t
ionthananyothercompanyintheindustry
.

x. Squarefol
lowsver
ytranspar
entmarketi
ngact
ivi
ti
es;
ther
eisno
misl
eadingorfr
aud,t
hat’swhyitenj
oysagoodreput
ati
onint
he
market.

xi
. Squar
emaint
ainshi
ghquali
tyst
andar
dsf
ori
tspr
oduct
s,t
hatwhyi
t
enj
oysagoodposit
ioni
nthemarket
.

xi
i
. Inproducti
onofSquar
e’sOmeprazoleI
nject
ion&DMPqual
i
tyi
ssues
aref
ollowed&maintai
nedproper
ly.

Thedesi
redACTCl
evel
areensur
ed100%

20
 Weakness
TheweaknessofSPLi st heanalysi
softheinternal i
ndust
rycomponents
thatarenotpr ovi
dingsignifi
cantaddedv al
ueorar einneedof
i
mpr ovement .Theinternalcomponentscani ncludephy si
calr
esources,
humancapi talorfeaturesthecompanycancont r
ol.Forexample,t
heSPL’s
weaknessescoul di ncl
udehi gh-
ri
skbusinessmodel i
ng,di
sengagedBoard
ofDirector
s,datedmedi calequi
pment,poorbr anding,l
owstaffmoraleor
diseconomiesofscal e.Mor eweaknessgi v
enbel ow:

I
. Squar
ehasi
ntr
oducedt
heOmepr
azol
eInj
ect
ionl
atei
nthemar
ket
.

I
I. Omeprazol
eInj
ect
ionhasi
ntr
oducedal
readybyI
ncept
a&popul
ar
bef
oreSquare.

I
II
. Squarehaslosttheoppor
tuni
tyt
obet
hef
ir
sti
ntr
oducer&can’
tenj
oy
thebenef
it
sofi t
.

I
V. Squareneedstoconsi
derthel
ossoflat
eint
roduct
ion&wor
kon
marketconsi
deri
ngthi
sdisadv
antage.

V. Lowinvest
mentsi
ninnovati
veR&Dcont
inuet
obeamaj
orweakness
ofSquarePhar
maceuti
calLt
d.

VI
. SPL’sl
acktheabi
li
tytocompet ewi
thMNCsforNewDr
ugDiscov
ery,
Resear
chandcommer ci
ali
zat
ionofmol
ecul
esonawor
ldwi
debasis
duetolackofr
esources.
21
VI
I. Strongli
nkagesbet
weenindust
ryandacademi
awhi
char
eessent
ial
forgrowthofthei
ndust
ryisl
acki
nginSPL.

VI
II
. Rapidl
yincreasi
ngcostsofskil
ledmanpowersuchassci
ent
ists/
regul
atorycomplianceper
sonnel/phar
maceuti
call
awyer
s/
i
nternati
onalbusi
nessdevelopmentper
sonneli
spushi
ngupt hecost
ofinnovati
on.

I
X. Salesandmar ket
ingknowledgeisi
nadequateduetolackof
understandi
ngofinter
nat
ionalPhar
maceut i
calmar
keting/
pri
ci
ng
practi
cesandmar ketenv
ironmenti
nvariouscount
ri
es.

X. I
nadequat
emanuf
act
uri
ngpr
act
ices.

Oppor
tuni
ti
es
TheopportunityofSPL’ si
stheanal ysi
soft heext
ernali
ndust
ry
componentst hatprovideachancef orthecompanyt ogrowinsome
capacit
yorgai nacompet it
iveedge.Theext er
nal
componentsshouldbe
envir
onmental fact
orsoraspect soutsi
det hecompany ’
scont
rol
,yet
ref
lecti
veofthebusi nessmar ket
place.Itcanbeanalyzedasunder.

I
. Int
hemar ket
,thenumberofAnt i
ulcerpat
ientsi
sincr
easi
ng,when
t
henumberofpat i
ent
sincreasesthepossibil
i
tyofagoodret
urnfr
om
t
herequi
reddrugincr
eases.

I
I. Ont
hatper
spect
iveweareseei
ngagoodopport
uni
tyf
orour
Omepr
azol
eInj
ecti
onsi
ncethemarketi
sgr
owing.

I
II
. I
ncr
edi
bleexpor
tpot
ent
ial
.

I
V. Newi
nnov
ati
vet
her
apeut
icpr
oduct
s.

22
 V. Dr
ugdel
i
ver
ysy
stem management
.

VI
. I
ncomei
sincr
easi
ngdaybyday
.

VI
I. Cl
i
nical
tri
als&r
esear
ch

VI
II
. Duetot hecostadvantageincontractmanufact
uri
ng&Research
multi
-nati
onalcompaniesf i
nditcompell
ingtoshif
tthei
rpr
oduct
ion
basestocountriesoff
eringsuchcostadv ant
age.

I
X. Li
censi
ngdeal
swi
thMNCsf
orNCEs(NewChemi cal
Ent
it
ies)and
NDDS(NewDrugDel
i
ver
ySy
stems)of
fernewopport
uni
ti
esforSPL.

X. Mar
keti
ngal
l
iancesforMNCproductsindomest
icandi
nter
nat
ional
mar
keti
sanotheremergi
ngoppor
tunit
y.

Ther
eisapossi
bil
i
tyofgr
eat
err
etur
nsf
rom ot
hercount
ri
esoft
he
worl
dbyexpor
ti
ng.

Thr
eat
s
Thet hr
eat
soft hephar maceuticalindustryistheanalysisoft heexternal
i
ndust r
ycomponent sthatcouldcr eateanoppor t
unityfort heSPLt o
decl
ine,at
rophyorl osesomecompet i
t i
veedge.Theext ernalcomponent s
shouldbeenv ir
onment alfact
orsoraspect soutsidethei ndustr
y’scontrol
,
yetrefl
ect
iveoft hebusinessmar ketplace.Forexampl e, the
pharmaceuticali
ndustry’
st hr
eatscoul dincludeincreasedgov ernment

23
regulat
ion,
adecl
ini
ngeconomy,i
ncreasingresearchanddevelopment
(R&D)costsoradecreasei
nthegl
obal populat
ion.Thethr
eatsofSPLare
discussedbel
ow.

I
. Someothercompani
esarepl
anni
ngori
npr
ocesst
oint
roduce
Omepr
azoleInj
ect
ioni
nthemarket
.

I
I. Whent heywi
ll
intr
oduce,t
heywillt
hroughacompeti
ti
oninthe
marketaswell
.Squareneedstoconsidert
hecompeti
ti
oninplanni
ng
oft
heirmarket
ingstr
ategi
estorespondtothi
sthr
eat&fightback.

I
II
. R&Deff
ort
sofBangl
adeshiphar
maceuti
calcompani
esar
ehamper
ed
byl
ackofenabl
i
ngregul
ator
yrequi
rement.

I
V. Exportef
for
tishamperedbypr
ocedur
alhur
dlesi
nBangl
adeshas
wellasnon-
tari
ffbar
ri
ersi
mposedabr
oad.

V. Loweri
ngoftar
if
fprot
ecti
onhasi
ncreasedcompet
it
ioni
ndomest
ic
market
sresul
ti
nginerosi
onofpr
ofi
tabi
li
ty.

VI
. Mergersandacqui
sit
ionsbyot
hercompani
esmaycompl
etel
y
changecondi
ti
onofthepharmamarket
.

VI
I. Smal
lnumberofdi
scov
eri
es.

VI
II
. Compet
it
ionf
rom MNCs.

I
X. Tr
ansf
ormat
ionofpr
ocesspat
entt
opr
oductpat
ent(
TRI
PS)
.

X. Out
dat
edSal
esandmar
ket
ingmet
hods.

XI
. Li
mit
edknowl
edgeandexper
iencebase.

XI
I. Pr
ici
ngandr
eimbur
sementl
evel
coul
drest
ri
ctuse.

24
 Chapt
er-Four
Recommendat
ion

I
. Qual
it
yandcontr
ol:Accordingt
ointer
nati
onalstandar
dsquar
e
phar
maceut
ical
sltd.shouldmaint
ainthei
rproductqual
it
y.

I
I. Local
mar ketshare:AtpresentinBangl adeshsquarepharmaceuti
calsi
s
themarketleaderinpharmaceuticalsector.I
tsfol
lowersand
competi
torsalwaystrytoincreasetheirpercent
ageofmar ketshare.So
squar
ephar maconcent r
atemor etoi ncreasehi
smar ketshar
e.

I
II
. .Forei
gnmar ket
:ThoughSPLcapturedAsi
a, Af
ri
ca,Mi
ddleEast
pharmaceut
icalmarketbutt
heEuropemar kett
il
lnowun-capt
ured.So
squarephar
mashoul dconcent
rat
emor einEuropemarket.

I
V. .Inv
entor
ymanagement :
Accordingtotherat
iot
hei
rinventor
y
managementsy st
em i
sstruggl
i
ngt heyshoul
dgi
vethissit
uati
on
topmostpri
ori
ty.

V. St
afft
rai
ning:ThoughSPLisaleadi
ngcompanybutit
smaxi
mum staf
fs
ar
enotwelltr
ained.Socompanyshoul
darr
angetr
aini
ngpr
ogram.

25
 Concl
usi
on
SquarePhar maceut ical
sLtd.hasav erygoodwor ki
ngenv ir
onmentwher e
theempl oyeesgetenoughoppor t
unitytoshowt hei
rabili
tyand
creati
veness.Itscommuni cationchannel i
ssuperb.I
nformal channel
of
communi cat
ioni sveryact
ive.Manyinterdepar
tmentalissuesaresolvedi
n
i
nf or
mal meet ings,
of t
enoveracupoft ea.I
ntr
oducti
onofLANhas
smoot henedt heprocess.

EverymemberofSquarePharmaceut i
calsLt d.feelsl
ikeheorsheisa
memberoft heSquaref
amily
.Thisfami l
yf eelingisabigassetfort
his
company.Mostoftheemployeesarededi catedandmot i
vatedtowork.
Sincegoodperf
ormanceisalwayshighli
ght edandcr eati
veideas
welcomedpeopleareeagert
ocontri
but ethei rbest.

SquarePhar maceut
ical
sLtd.bel
ievesinhonestyinever
yphaseof
business.Themanagementpr omotesthisi
deat oit
sworkers.Theimage
ofthecompanyi salsogoodalloverthecountr
y.Customersallov
erthe
countryrecogni
zeSquareasaqual i
tycompanyandanhonestcompany .

26
 Ref
erence
 www.squarepharma.
com.bd
 Bookl
etspubli
shedbySquarePhar
maceut
ical
slt
d
 En.Wi
kipedia.
org/wi
ki
/squar
ephar
maceut
ical
s

27